Respiratory Distress Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Respiratory Distress Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A8190
Buy Now

Market Overview:

The 7 major respiratory distress syndrome markets are expected to exhibit a CAGR of 4.56% during 2024-2034.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2034
Historical Years
2018-2023
Market Growth Rate 2024-2034 4.56%


The respiratory distress syndrome market has been comprehensively analyzed in IMARC's new report titled "Respiratory Distress Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Respiratory distress syndrome, also referred to as hyaline membrane disease, is a respiratory condition that primarily affects premature infants. This illness leads to insufficient production of a substance called surfactant in the lungs, which helps to keep the air sacs (alveoli) open and prevents their collapse during exhalation. As a result, infants suffering from the ailment may experience difficulty breathing enough oxygen and expelling carbon dioxide. Various other common symptoms associated with the disease include rapid and shallow breathing, grunting sounds during exhalation, flaring of the nostrils, a bluish discoloration of the skin, retractions, a faster-than-normal heart rate, etc. The diagnosis of respiratory distress syndrome typically involves a combination of medical history, clinical indications, and a physical examination. A chest X-ray is often performed to evaluate the patient's lung structure and look for characteristic signs of the ailment, such as a ground-glass appearance, air bronchograms, and reduced lung expansion. The healthcare provider may further conduct a blood gas analysis to measure the oxygen and carbon dioxide levels in the blood.

The increasing cases of premature births that affect the normal growth of the lung or the production of surfactant in infants are primarily driving the respiratory distress syndrome market. In addition to this, the rising prevalence of maternal smoking, which can trigger an inflammatory response and generate oxidative stress in the developing fetus, is also bolstering the market growth. Moreover, the widespread adoption of continuous positive airway pressure therapy, since it works by opening the air sacs to help in maintaining lung volume and preventing the collapse of alveoli during expiration, is acting as another significant growth-inducing factor. Apart from this, the escalating application of surfactant replacement therapy, which restores the deficient surfactant in the lungs of patients, thereby boosting the oxygenation capacity of the lungs, reducing surface tension, and promoting pulmonary functions, is further creating a positive outlook for the market. Additionally, the emerging popularity of high-frequency oscillatory ventilation techniques over conventional procedures owing to the decreased risk of lung injury associated with high pressures, is expected to drive the respiratory distress syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the respiratory distress syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for respiratory distress syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the respiratory distress syndrome market in any manner.

Recent Developments:

  • In October 2023, GEn1E Lifesciences Inc. was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of the company's new therapy for acute respiratory distress syndrome. This will help to accelerate the development of GEn1E's new, first-of-its-kind p38a: MK2 Signal Modifier treatment for acute respiratory distress syndrome.


Key Highlights:

  • Respiratory distress syndrome is typically seen in preterm newborns due to surfactant deficit (93% of infants under 28 weeks).
  • Approximately 10% of late preterm newborns and 1% of term neonates may have respiratory distress syndrome.
  • The American Lung Association reports that around 190,000 Americans are diagnosed with acute respiratory distress syndrome each year.
  • The mortality rate of respiratory distress syndrome remains high, over 40 percent.
  • The most common causes of respiratory distress in neonates were transient tachypnea of the newborn (TTN) (22.0%), meconium aspiration syndrome (MAS) (16.90%), respiratory distress syndrome (RDS) (20%), sepsis (14%), and perinatal asphyxia (12%).


Drugs:

Infasurf (calfactant) is a sterile and non-pyrogenic lung surfactant. Infasurf is specifically suggested to prevent respiratory distress syndrome in preterm newborns at high risk for respiratory distress syndrome, as well as to treat (rescue) premature infants who develop the disease.

GEn-1124 is under development by GEn1E Lifesciences for the treatment of acute respiratory distress syndrome. The drug candidates work by targeting mitogen-activated protein kinase 14 (MAP Kinase p38 Alpha). It is delivered via the intravenous method.

Glenzocimab is a monoclonal antibody fragment that is entirely humanized and targets the human platelet glycoprotein VI (GPVI), which is implicated in thrombus development, growth, and stability.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the respiratory distress syndrome market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the respiratory distress syndrome market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current respiratory distress syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance    
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Infasurf (Calfactant) Ony
Curosurf (Poractant alfa) Chiesi/Karolinska Institute
GEn-1124 GEn1E Lifesciences
BAY 1211163 Bayer
Veru-111 Veru Healthcare
Reparixin Dompe Farmaceutici
Glenzocimab Acticor Biotech


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the respiratory distress syndrome market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the respiratory distress syndrome market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the respiratory distress syndrome market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of respiratory distress syndrome across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of respiratory distress syndrome by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of respiratory distress syndrome by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with respiratory distress syndrome across the seven major markets?
  • What is the size of the respiratory distress syndrome patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of respiratory distress syndrome?
  • What will be the growth rate of patients across the seven major markets?
     

Respiratory Distress Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for respiratory distress syndrome drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the respiratory distress syndrome market?
  • What are the key regulatory events related to the respiratory distress syndrome market?
  • What is the structure of clinical trial landscape by status related to the respiratory distress syndrome market?
  • What is the structure of clinical trial landscape by phase related to the respiratory distress syndrome market?
  • What is the structure of clinical trial landscape by route of administration related to the respiratory distress syndrome market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Respiratory Distress Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More